The invention provides a cancer antigen peptide, which can be used as a cancer peptide vaccine to apply to a wide range of cancer patients without HLA typing detection, and is not limited to patients with specific HLA typing. The peptide with 4 CTL epitopes was obtained by connecting 4 CTL epitopes selected from the CTL epitope peptide group reported to have CTL induction ability and derived from tumor antigen molecules through the junction.本發明提供一種癌症抗原肽，所述癌症抗原肽可以作爲癌症的肽疫苗施用於廣泛的癌症患者而不需要HLA分型檢測，且不限定於具有特定的HLA分型的患者。通過將選自報道具有CTL誘導能力、且源自腫瘤抗原分子的CTL表位肽組中的4個CTL表位肽經由接頭連接而得到具有4個連接的CTL表位的肽。
